Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.56
-0.05 (-0.52%)
At close: Jun 27, 2025, 4:00 PM
9.54
-0.02 (-0.21%)
After-hours: Jun 27, 2025, 7:42 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
According to 20 professional analysts, the 12-month price target for Intellia Therapeutics stock ranges from a low of $10 to a high of $68. The average analyst price target of $36.6 forecasts a 282.85% increase in the stock price over the next year.
Price Target: $36.60 (+282.85%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 7 | 6 | 6 | 7 | 7 | 7 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 17 | 18 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | Jun 16, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $74 → $54 | Strong Buy | Maintains | $74 → $54 | +464.85% | Jun 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | May 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | May 20, 2025 |
| Wedbush | Wedbush | Hold Reiterates $10 | Hold | Reiterates | $10 | +4.60% | May 19, 2025 |
Financial Forecast
Revenue This Year
57.69M
from 57.88M
Decreased by -0.32%
Revenue Next Year
50.74M
from 57.69M
Decreased by -12.04%
EPS This Year
-4.29
from -5.25
EPS Next Year
-4.05
from -4.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 220.5M | 105.0M | 384.3M | ||
| Avg | 57.7M | 50.7M | 89.4M | ||
| Low | 16.3M | 6.9M | 3.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 281.0% | 82.0% | 657.3% | ||
| Avg | -0.3% | -12.0% | 76.2% | ||
| Low | -71.8% | -88.1% | -93.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.50 | -2.27 | -1.72 | ||
| Avg | -4.29 | -4.05 | -3.74 | ||
| Low | -5.44 | -5.44 | -5.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.